Subtopic Deep Dive
Gaucher Disease Enzyme Therapy
Research Guide
What is Gaucher Disease Enzyme Therapy?
Gaucher Disease Enzyme Therapy encompasses glucocerebrosidase replacement therapies using recombinant enzymes like imiglucerase (Cerezyme®) to treat glucocerebrosidase deficiency in Gaucher disease patients.
Gaucher disease results from lysosomal glucocerebrosidase deficiency causing glucosylceramide accumulation in macrophages. Enzyme replacement therapy (ERT) delivers mannose-terminated recombinant glucocerebrosidase to target macrophages. Key papers include Stirnemann et al. (2017, 823 citations) reviewing pathophysiology and treatments, and Pastores et al. (2004, 423 citations) defining therapeutic goals.
Why It Matters
ERT with imiglucerase transformed Gaucher disease management by reducing hepatosplenomegaly, improving hematologic parameters, and ameliorating bone disease (Stirnemann et al., 2017). Plant-derived glucocerebrosidase (taliglucerase alfa) offers scalable production with terminal mannose glycans for macrophage targeting (Shaaltiel et al., 2007). Optimizing dosing and monitoring immune responses enhances long-term outcomes in type 1 and neuronopathic forms (Pastores et al., 2004).
Key Research Challenges
Immune Response to ERT
Patients develop antibodies against recombinant glucocerebrosidase, reducing efficacy and causing hypersensitivity. Monitoring IgG titers and infusion reactions remains critical (Stirnemann et al., 2017). Strategies to mitigate immunogenicity are needed for lifelong therapy.
Bone Disease Persistence
ERT improves visceral symptoms but bone crises and avascular necrosis persist in some patients despite treatment. Long-term skeletal outcomes require optimized dosing (Pastores et al., 2004). Imaging biomarkers for bone response assessment are underdeveloped.
Production Scalability
CHO cell systems for imiglucerase face high costs; plant cell systems enable mannose-glycan engineering for better uptake but need validation (Shaaltiel et al., 2007). Ensuring consistent glycosylation and activity across batches poses manufacturing challenges.
Essential Papers
Fabry disease
Dominique P. Germain · 2010 · Orphanet Journal of Rare Diseases · 1.1K citations
Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A activity. FD is pan-ethnic and the reported a...
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Jérôme Stirnemann, Nadia Belmatoug, Fabrice Camou et al. · 2017 · International Journal of Molecular Sciences · 823 citations
Gaucher disease (GD, ORPHA355) is a rare, autosomal recessive genetic disorder. It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its subst...
Lysosomes as a therapeutic target
Srinivasa Reddy Bonam, Fengjuan Wang, Sylviane Muller · 2019 · Nature Reviews Drug Discovery · 718 citations
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
J. E. Wraith, Maurizio Scarpa, Michael Beck et al. · 2007 · European Journal of Pediatrics · 504 citations
Therapeutic goals in the treatment of Gaucher disease
Gregory M. Pastores, Neal J. Weinreb, Johannes M. F. G. Aerts et al. · 2004 · Seminars in Hematology · 423 citations
Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system
Yoseph Shaaltiel, Daniel Bartfeld, Sharon Hashmueli et al. · 2007 · Plant Biotechnology Journal · 417 citations
Summary Gaucher's disease, a lysosomal storage disorder caused by mutations in the gene encoding glucocerebrosidase (GCD), is currently treated by enzyme replacement therapy using recombinant GCD (...
Lysosomal Storage Diseases: From Pathophysiology to Therapy
Giancarlo Parenti, Generoso Andria, Andrea Ballabio · 2015 · Annual Review of Medicine · 398 citations
Lysosomal storage diseases are a group of rare, inborn, metabolic errors characterized by deficiencies in normal lysosomal function and by intralysosomal accumulation of undegraded substrates. The ...
Reading Guide
Foundational Papers
Start with Pastores et al. (2004, 423 citations) for therapeutic goals in ERT; then Shaaltiel et al. (2007, 417 citations) for production innovations enabling mannose-targeted glucocerebrosidase.
Recent Advances
Stirnemann et al. (2017, 823 citations) provides comprehensive pathophysiology and treatment updates; Parenti et al. (2015, 398 citations) contextualizes lysosomal therapies.
Core Methods
Recombinant glucocerebrosidase production in CHO or plant cells with mannose-6-phosphate glycans for macrophage uptake; biweekly IV dosing monitored by chitotriosidase levels and MRI.
How PapersFlow Helps You Research Gaucher Disease Enzyme Therapy
Discover & Search
Research Agent uses searchPapers('Gaucher Disease enzyme replacement therapy glucocerebrosidase') to retrieve Stirnemann et al. (2017, 823 citations), then citationGraph reveals Pastores et al. (2004) as highly cited foundational work, and findSimilarPapers uncovers Shaaltiel et al. (2007) on plant-derived enzymes.
Analyze & Verify
Analysis Agent employs readPaperContent on Shaaltiel et al. (2007) to extract mannose glycan data, runPythonAnalysis to plot enzyme uptake kinetics from supplementary tables using pandas, and verifyResponse with CoVe checks claims against GRADE B evidence from Stirnemann et al. (2017) review.
Synthesize & Write
Synthesis Agent detects gaps in neuronopathic Gaucher ERT data via contradiction flagging across Pastores et al. (2004) and Stirnemann et al. (2017); Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to integrate 20+ refs, and latexCompile for PDF output with exportMermaid diagrams of ERT pathways.
Use Cases
"Analyze immune response rates in Gaucher ERT patients from 10 key papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (meta-analysis of antibody titers with pandas/statsmodels) → statistical verification output with p-values and forest plots.
"Write LaTeX review section on taliglucerase vs imiglucerase efficacy"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Pastores 2004, Shaaltiel 2007) → latexCompile → camera-ready PDF section.
"Find code for glucocerebrosidase enzyme kinetics modeling"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Jupyter notebook for Michaelis-Menten simulations.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(ERT Gaucher) → 50+ papers → DeepScan 7-step analysis with GRADE scoring → structured report on dosing outcomes (Stirnemann 2017). Theorizer generates hypotheses on plant vs CHO ERT immunogenicity from Shaaltiel (2007) and Pastores (2004). Chain-of-Verification validates claims across citationGraph clusters.
Frequently Asked Questions
What is Gaucher Disease Enzyme Therapy?
ERT replaces deficient glucocerebrosidase with recombinant enzymes like imiglucerase (Cerezyme®) or taliglucerase, targeting mannose receptors on macrophages (Stirnemann et al., 2017).
What are main ERT methods for Gaucher?
Intravenous infusions of CHO-produced imiglucerase or plant-produced taliglucerase alfa with terminal mannose glycans for lysosomal delivery (Shaaltiel et al., 2007).
What are key papers on Gaucher ERT?
Stirnemann et al. (2017, 823 citations) reviews treatments; Pastores et al. (2004, 423 citations) defines therapeutic goals; Shaaltiel et al. (2007, 417 citations) details plant production.
What are open problems in Gaucher ERT?
Anti-drug antibodies reduce efficacy; bone disease persists; scalable low-immunogenic production needed (Stirnemann et al., 2017; Pastores et al., 2004).
Research Lysosomal Storage Disorders Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Gaucher Disease Enzyme Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers